DOPAMINE METABOLISM IN THE CENTRAL NERVOUS-SYSTEM AFTER DISCONTINUATION OF L-DOPA THERAPY IN PATIENTS WITH PARKINSON DISEASE

被引：49
|
作者：
OGASAHARA, S
NISHIKAWA, Y
TAKAHASHI, M
WADA, K
NAKAMURA, Y
YORIFUJI, S
TARUI, S
机构：
来源：
JOURNAL OF THE NEUROLOGICAL SCIENCES | 1984年 / 66卷 / 2-3期
关键词：
D O I：
10.1016/0022-510X(84)90003-0
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：151 / 163
页数：13
相关论文
共 50 条
  • [21] Treatment strategies in Parkinson's disease after a quarter century experiences with L-DOPA therapy
    Fischer, PA
    JOURNAL OF NEURAL TRANSMISSION-SUPPLEMENT, 1995, (46): : 381 - 389
  • [22] Unpredictable Rotational Responses to L-dopa in the Rat Model of Parkinson's Disease: the Role of L-dopa Pharmacokinetics and Striatal Dopamine Depletion
    Kaariainen, Tiina M.
    Kaenmaki, Mikko
    Forsberg, Markus M.
    Oinas, Niko
    Tammimaki, Anne
    Mannisto, Pekka T.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2012, 110 (02) : 162 - 170
  • [23] EXCRETION OF L-DOPA AND ITS METABOLITES IN URINE OF PARKINSONS DISEASE PATIENTS RECEIVING L-DOPA THERAPY
    ROUTH, JI
    BANNOW, RE
    FINCHAM, RW
    STOLL, JL
    CLINICAL CHEMISTRY, 1971, 17 (09) : 867 - +
  • [24] METABOLISM AND ABSORPTION OF L-DOPA IN PATIENTS WITH PARKINSONS-DISEASE
    KANEDA, M
    TAKEUCHI, S
    KURUMA, I
    YOKOCHI, M
    NARABAYASHI, H
    JAPANESE JOURNAL OF PHARMACOLOGY, 1976, 26 : P54 - P54
  • [25] The impact of L-DOPA and entacapon therapy on plasma level of homocysteine in Parkinson's disease patients
    Nevrly, M.
    Kanovsky, P.
    Vranova, H.
    Nestrasil, I.
    Langova, K.
    CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE, 2008, 71 (01) : 55 - 60
  • [26] Chronic L-DOPA therapy alters central serotonergic function and L-DOPA-induced dopamine release in a region-dependent manner in a rat model of Parkinson's disease
    Navailles, Sylvia
    Bioulac, Bernard
    Gross, Christian
    De Deurwaerdere, Philippe
    NEUROBIOLOGY OF DISEASE, 2011, 41 (02) : 585 - 590
  • [27] Conversion of L-dopa to Extended Release L-dopa (Rytary®) in Patients with Fluctuating Parkinson's Disease: Predictors of Dose
    Ondo, William
    Coss, Pablo
    Christie, Melissa
    Pascual, Belen
    JOURNAL OF PARKINSONS DISEASE, 2019, 9 (01) : 153 - 156
  • [28] Starting therapy in Parkinson's disease with L-dopa or agonists and the occurrence of late L-dopa motor problems in daily practice
    Horstink, M. W. I. M.
    Haaxma, C. A.
    Borm, G. F.
    Bloem, B. R.
    MOVEMENT DISORDERS, 2007, 22 : S235 - S236
  • [29] Pupillometry as an indicator of l-DOPA dosages in Parkinson’s disease patients
    O. Bartošová
    C. Bonnet
    O. Ulmanová
    M. Šíma
    F. Perlík
    E. Růžička
    O. Slanař
    Journal of Neural Transmission, 2018, 125 : 699 - 703
  • [30] The Effect of L-dopa on Postural Stability in Parkinson's Disease Patients
    Wilczynski, Jacek
    Habik, Natalia
    APPLIED SCIENCES-BASEL, 2019, 9 (03):
12345